All Updates

All Updates

icon
Filter
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Clinical Trial Technology
Sep 13, 2024
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Sep 13, 2024

Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment

Partnerships

  • Massive Bio, an AI-driven clinical trial matching platform provider, has partnered with Foundation Medicine, a leader in next-gen sequencing, to increase patient access to cancer clinical trials.

  • The collaboration aims to address the low rate of patient enrollment in oncology clinical trials by combining Massive Bio's AI-driven patient-matching technology with Foundation Medicine's expertise in genomic profiling. The partnership will leverage shared data and AI analytics to enhance clinical trial matching speed and accuracy, potentially improving patient outcomes globally.

  • Through this partnership, both companies aim to use their networks and capabilities across the healthcare landscape, employing advanced AI techniques and a robust digital health platform to refine clinical trial processes and enhance precision oncology.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.